Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE versus PROCHLORPERAZINE EDISYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE versus PROCHLORPERAZINE EDISYLATE.
FLUPHENAZINE vs PROCHLORPERAZINE EDISYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with high potency and additional antagonism at alpha-adrenergic, muscarinic, and histaminergic receptors.
Prochlorperazine is a phenothiazine antipsychotic that antagonizes dopamine D2 receptors in the brain, particularly in the chemoreceptor trigger zone, exerting antiemetic effects. It also blocks alpha-adrenergic and muscarinic receptors.
Fluphenazine decanoate (long-acting): 12.5-25 mg IM every 2 weeks; Fluphenazine hydrochloride (oral): 2.5-10 mg daily in divided doses; initial titration 2.5-10 mg/day, maintenance 1-5 mg/day. Maximum oral dose 20 mg/day.
Antiemetic: 5-10 mg IM/IV every 3-4 hours as needed, maximum 40 mg/day; or 25 mg PR twice daily. Antipsychotic: 10-20 mg IM/IV every 1-4 hours, maximum 40 mg/day; oral: 5-10 mg 3-4 times daily, maximum 150 mg/day.
None Documented
None Documented
Clinical Note
moderateFluphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate."
Clinical Note
moderateFluphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Fluphenazine."
Clinical Note
moderateFluphenazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life is 15-30 hours, but may extend to 40-50 hours after chronic use; clinical context: dosing interval is typically 12-24 hours, and steady-state is reached within 3-5 days.
Terminal elimination half-life is approximately 6-8 hours, but may be prolonged to 10-12 hours in elderly patients or those with hepatic impairment. In overdoses, half-life can extend beyond 24 hours.
Primarily hepatic metabolism with biliary excretion. Less than 1% excreted unchanged in urine; fecal elimination accounts for approximately 20-30% of metabolites.
Primarily renal excretion of metabolites (approximately 70-80% as conjugated metabolites), with less than 1% excreted unchanged. Fecal excretion accounts for about 20-30% via biliary elimination.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic
Fluphenazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine."